glp 1 and substance use disorder GLP-1 receptor agonists disorders: new large-scale evidence from the BMJ A cohort study published in the BMJ this week (Cai, Choi, Xie, Al-Aly, 2026) examined over 600,000 US veterans GLP-1 weight-loss drugs show early

The current treatment for osteoporosis is mainly the inhibition of bone resorption

Our BPC-157 supplement remains stable in the stomach

(Source 3) Can You Extract Enough Glutathione from Food

A long road is ahead of us to better understand the complexity of HFpEF, but a comprehensive multimarker approach may be recommended to characterise specific HFpEF phenotypes/endotypes for optimising therapy and to stratify risk

Investigational uses in heart failure, NASH, and neurodegeneration are currently being explored, often leveraging multi-receptor agonist platforms that combine GLP-1, GIP, and glucagon receptor activation

No clinical trial has studied this combination safely